Now to be specific NYR is the only drug in the world to inhibit TRPC 3,6 and 7 calcium ion receptors. It’s the first of its kind and now reached the clinic. If we go into further research the only other drug in trial in this class is below:
TRPC6 Inhibitor BI 764198 currently in phase 2 Focal Segmental Glomerulosclerosis treatment.
This means the new indication coming up for NYR is highly likely going to be the treatment of Focal Glomerulosclerosis of the kidney a 24 billion dollar unmet market.
Knowing that NYR targets all 3 major calcium ion channels on the kidney compared to Inhibitor BI 764198, NYR will produce a better outcome and knowing Bi 764198 has passed safety studies it puts NYR in a very good position .
NYR will be taken over after phase 2 and be worth north of a billion dollars. Big pharma will not let it get to its maximum potential. But CEO stated they will be licensing out the drug after phase 2 anyway
NYR Price at posting:
9.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)